However, aberrant activation of the NLRP3 inflammasome is implicated in various diseases including diabetes, atherosclerosis, metabolic syndrome, cardiovascular, and neurodegenerative diseases; ...

Furthermore, we undertook this study to demonstrate that NLRP3 inhibitor treatment reduces inflammasome-derived neuroinflammation and white matter damage caused by chronic ischemia. Methods: We used ...

our peripherally restricted NLRP3 inhibitor and VTX3232, our CNS-penetrant NLRP3 inhibitor,” said Raju Mohan, PhD, President and Chief Executive Officer. “With three trials expected to be ...

Meanwhile, the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome can not only lead to the occurrence of inflammatory response, but also induce ...

(NASDAQ:VTYX), a biopharmaceutical company trading near its 52-week low of $1.67, has commenced Phase 2 trials for its NLRP3 inhibitor portfolio, targeting various inflammatory and ...

(Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative ...

(Nasdaq: VTYX) ("Ventyx”, "Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative ...